HROW Stock Risk & Deep Value Analysis
Harrow Inc
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About HROW Stock
We analyzed Harrow Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran HROW through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is HROW Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
Medium
What Are the Red Flags for HROW?
- ⚠
Higher-than-expected cash burn and continued need for dilutive financing
- ⚠
Failed or slow integration of acquired assets, leading to missed revenue targets
- ⚠
Increased competition from larger pharmaceutical companies entering the ophthalmic niche
- ⚠
Adverse regulatory decisions or product setbacks
Unlock HROW Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Harrow Inc (HROW) Do?
Market Cap
$1.88B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
382
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Visit Harrow Inc WebsiteIs HROW Stock Undervalued?
Unlock the full AI analysis for HROW
Get the complete DVR score, risk analysis, and more
Does HROW Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is strengthening as Harrow continues to acquire and integrate specialized ophthalmic products and leverage its distribution. Intellectual property and regulatory hurdles create barriers to entry, while scale benefits from consolidation can drive cost efficiencies. Durability depends on continued successful execution and protection of IP.
Moat Erosion Risks
- •Failure to successfully integrate acquired companies and products, leading to loss of value and operational inefficiencies.
- •Expiration of key product patents or emergence of generic competition.
- •Increased competitive pressure from larger pharmaceutical companies entering or expanding in the ophthalmic market.
HROW Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive HROW Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (Estimated early-May 2026)
- •Successful integration and sales ramp of recent ophthalmic product acquisitions
- •Pipeline updates or new product launches within the next 6 months
Medium-Term (6-18 months)
- •Achievement of positive operating cash flow and reduced cash burn (6-18 months)
- •Strategic partnerships or further accretive M&A activity
- •Meaningful reduction in net debt through improved profitability and cash generation
Long-Term (18+ months)
- •Establishment as a dominant, profitable specialty pharmaceutical platform in ophthalmology
- •Expansion into new therapeutic areas or international markets beyond ophthalmology
- •Sustained organic growth driven by a robust product portfolio and distribution network
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for HROW?
- ✓
Acceleration in organic revenue growth rates (excluding new acquisitions)
- ✓
Consistent reduction in quarterly cash burn and progress towards positive free cash flow
- ✓
Successful debt refinancing or reduction and improved balance sheet metrics
- ✓
Expansion of gross margins and operating margins
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for HROW (Harrow Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
